- Home
- LMB vs GYRE Comparison
LMB vs GYRE Comparison
Compare LMB & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LMB
- GYRE
- Stock Information
- Founded
- LMB 1901
- GYRE 2002
- Country
- LMB United States
- GYRE United States
- Employees
- LMB N/A
- GYRE N/A
- Industry
- LMB Engineering & Construction
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- LMB Consumer Discretionary
- GYRE Health Care
- Exchange
- LMB Nasdaq
- GYRE Nasdaq
- Market Cap
- LMB 1.1B
- GYRE 1.1B
- IPO Year
- LMB 2014
- GYRE N/A
- Fundamental
- Price
- LMB $104.65
- GYRE $10.70
- Analyst Decision
- LMB Strong Buy
- GYRE
- Analyst Count
- LMB 2
- GYRE 0
- Target Price
- LMB $106.50
- GYRE N/A
- AVG Volume (30 Days)
- LMB 186.8K
- GYRE 120.1K
- Earning Date
- LMB 03-12-2025
- GYRE 11-13-2024
- Dividend Yield
- LMB N/A
- GYRE N/A
- EPS Growth
- LMB 29.01
- GYRE N/A
- EPS
- LMB 2.18
- GYRE N/A
- Revenue
- LMB $517,822,000.00
- GYRE $105,033,000.00
- Revenue This Year
- LMB $2.59
- GYRE $25.32
- Revenue Next Year
- LMB $12.46
- GYRE $12.95
- P/E Ratio
- LMB $48.04
- GYRE N/A
- Revenue Growth
- LMB 0.13
- GYRE N/A
- 52 Week Low
- LMB $38.03
- GYRE $8.26
- 52 Week High
- LMB $107.00
- GYRE $26.37
- Technical
- Relative Strength Index (RSI)
- LMB 63.64
- GYRE 46.85
- Support Level
- LMB $91.28
- GYRE $10.58
- Resistance Level
- LMB $100.99
- GYRE $11.36
- Average True Range (ATR)
- LMB 6.00
- GYRE 0.73
- MACD
- LMB 0.96
- GYRE 0.06
- Stochastic Oscillator
- LMB 95.00
- GYRE 35.63
About LMB Limbach Holdings Inc.
Limbach Holdings Inc is a commercial specialty contractor in the fields of heating, ventilation, air conditioning, plumbing, electrical, and building controls for the design and construction of new and renovated buildings, maintenance services, energy retrofits, and equipment upgrades. It operates in two segments namely General Contractor Relationships (GCR) and Owner Direct Relationships (ODR). The company generates maximum revenue from the ODR segment.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.